Bifogade filer
Kurs
-1,42%
Likviditet
0,79 MSEK
Prenumeration
Kalender
Tid* | ||
2025-08-22 | 09:00 | Kvartalsrapport 2025-Q2 |
2025-05-08 | 09:00 | Kvartalsrapport 2025-Q1 |
2025-02-20 | 09:00 | Bokslutskommuniké 2024 |
2024-10-31 | - | Kvartalsrapport 2024-Q3 |
2024-08-23 | - | Kvartalsrapport 2024-Q2 |
2024-05-08 | - | X-dag ordinarie utdelning LUMITO 0.00 SEK |
2024-05-07 | - | Årsstämma |
2024-05-07 | - | Kvartalsrapport 2024-Q1 |
2024-02-22 | - | Bokslutskommuniké 2023 |
2023-10-31 | - | Kvartalsrapport 2023-Q3 |
2023-08-17 | - | Kvartalsrapport 2023-Q2 |
2023-05-26 | - | X-dag ordinarie utdelning LUMITO 0.00 SEK |
2023-05-25 | - | Årsstämma |
2023-05-03 | - | Kvartalsrapport 2023-Q1 |
2023-02-23 | - | Bokslutskommuniké 2022 |
2022-11-02 | - | Kvartalsrapport 2022-Q3 |
2022-08-18 | - | Kvartalsrapport 2022-Q2 |
2022-05-30 | - | X-dag ordinarie utdelning LUMITO 0.00 SEK |
2022-05-27 | - | Årsstämma |
2022-05-06 | - | Kvartalsrapport 2022-Q1 |
2022-02-17 | - | Bokslutskommuniké 2021 |
2021-11-24 | - | Extra Bolagsstämma 2021 |
2021-10-20 | - | Kvartalsrapport 2021-Q3 |
2021-08-18 | - | Kvartalsrapport 2021-Q2 |
2021-05-28 | - | X-dag ordinarie utdelning LUMITO 0.00 SEK |
2021-05-27 | - | Årsstämma |
2021-04-28 | - | Kvartalsrapport 2021-Q1 |
2021-02-17 | - | Bokslutskommuniké 2020 |
2020-11-03 | - | Kvartalsrapport 2020-Q3 |
2020-08-20 | - | Kvartalsrapport 2020-Q2 |
2020-05-28 | - | X-dag ordinarie utdelning LUMITO 0.00 SEK |
2020-05-27 | - | Årsstämma |
2020-04-28 | - | Kvartalsrapport 2020-Q1 |
2020-02-17 | - | Bokslutskommuniké 2019 |
2019-10-31 | - | Kvartalsrapport 2019-Q3 |
2019-08-21 | - | Kvartalsrapport 2019-Q2 |
2019-06-04 | - | Årsstämma |
2019-05-23 | - | X-dag ordinarie utdelning LUMITO 0.00 SEK |
2019-04-30 | - | Kvartalsrapport 2019-Q1 |
2019-02-15 | - | Bokslutskommuniké 2018 |
Beskrivning
Land | Sverige |
---|---|
Lista | Nordic SME Sweden |
Sektor | Hälsovård |
Industri | Medicinteknik |
Lumito has now launched a new website. The website is designed to better reflect Lumito's ongoing commercialisation phase, with a special focus on the SCIZYS product ahead of the upcoming product launch.
Visit our new website here!
For further information, please contact:
Mattias Lundin, CEO Lumito
E-mail: ml@lumito.se
Ph: +46 76 868 45 09
Lumito
Lumito specialises in medical technology for digital pathology. Through its proprietary and patented technology, Lumito aims to provide healthcare providers with a powerful tool to meet the demands for fast and safe tissue diagnostics in personalised healthcare. The technology enables higher-contrast images without irrelevant background information, making it easier for pathologists to find cancer indications. The technology, based on Up Converting NanoParticles (UCNP), has the potential to significantly improve the diagnosis of tissue samples through higher quality analyses and shortened analysis times. The method has several potential applications, but Lumito has focused primarily on digital pathology and first on a release of SCIZYS by Lumito for use in research laboratories. The company is a spin-off of a research group at the Department of Atomic Physics and Laser Centre. www.lumito.se/en
The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.
Attachments
Lumito launches new website